Correction To: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-In-Human, Single- And Multiple-Dose Study in Healthy Volunteers
Clinical Drug Investigation - United Kingdom
doi 10.1007/s40261-019-00832-2
Full Text
Open PDFAbstract
Available in full text
Date
July 23, 2019
Authors
Publisher
Springer Science and Business Media LLC